Talphera, Inc.

TLPH Healthcare Drug Manufacturers Specialty & Generic

In the quarter to June 2026, revenue fell 99.6%, EPS grew 40.0% and free cash flow fell 33.1%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years; insiders bought in the last twelve months.

1.08 0.01 +0.93%
Market cap
$55.5M
P/E
0.0×
Fwd P/E
−3.1×
Dividend yield
—
F-score
n/a
Altman Z
−20.73
Beneish M
n/a
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
0.00 — 0.00 0.34 0.00 0.00 0.00 0.00 0.00 0.00
Piotroski F-Score
— — 4 3 4 4 1 4 2 1
P/S ratio
113.49 — 11.69 9.26 23.82 19.52 72.99 62.73 12.02 6.66
Altman Z-Score
(20.73) — (31.77) (13.61) (9.15) (10.17) (6.52) (3.35) (5.80) (2.71)
Altman Z″-Score (non-manufacturers)
(49.59) — (71.94) (30.43) (20.56) (23.31) (14.35) (6.27) (12.32) (5.06)
P/FCF ratio
0.00 — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Beneish M-Score
— — — — — — — — — (1.19)
P/Operating CF
(19.85) — (2.67) (3.03) (8.39) (16.71) (11.80) (15.01) (14.40) (11.20)
P/B ratio
2.84 — 0.75 0.75 0.00 0.00 0.00 31.73 0.00 0.00
Price to Tangible BV
2.84 — 0.75 0.75 0.00 0.00 0.00 31.73 0.00 0.00
EV/Sales
80.58 — 8.34 2.27 12.17 15.64 55.08 19.16 6.85 3.27
EV/EBITDA
0.00 — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(3.02) — (0.43) (0.14) (1.14) (2.20) (2.46) (1.42) (1.84) (1.93)
EV/FCF
(3.93) — (0.51) (0.13) (1.08) (2.10) (2.31) (1.38) (1.70) (1.71)
Quick Ratio
5.35 3.35 2.08 1.51 2.53 2.47 4.89 6.66 4.54 8.45
Current Ratio
5.49 3.56 2.57 1.78 2.73 2.66 5.27 6.78 4.64 8.74
Net Debt/EBITDA
1.50 0.58 0.57 0.65 0.97 0.54 0.78 2.67 1.12 1.96
Debt/Assets
0.00% 0.00% 0.00% 11.29% 17.72% 33.00% 27.53% 9.95% 25.28% 21.55%
Debt/Equity
0.00 0.00 0.00 0.25 (0.38) (0.39) (0.61) 2.82 (0.52) (4.04)
Asset Turnover
0.00 0.00 0.02 0.03 0.04 0.07 0.02 0.02 0.09 0.15
Operating CF/Net income
0.80 0.98 0.95 (0.67) 0.85 0.95 0.96 0.62 0.58 0.68
Capex/Depreciation
0.00 0.00 9.14 (1.25) (0.93) (1.00) (2.08) (1.42) (1.38) (1.81)
Interest Coverage
— (38.71) (126.04) (22.67) 48.15 8,192.60 (45.25) (2.84) (2.76) (2.63)
ROE
(114.16%) (117.65%) (102.44%) (601.31%) 76.60% 83.11% 286.51% 292.34% 246.18% (310.75%)
ROA
(59.60%) (67.32%) (54.20%) 67.52% (48.69%) (51.23%) (50.25%) (48.09%) (58.68%) (37.89%)
ROIC
0.00% 0.00% (223.45%) (246.80%) 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(83.61%) (192.08%) (260.43%) 392.08% (73.26%) (90.02%) (73.30%) (45.53%) (84.71%) (48.18%)
Average Days of Receivables
0.00 — 0.00 0.00 20.72 42.79 68.89 68.05 69.99 122.66
Research and Development Expense of Revenue
21,546.43% 0.00% 851.92% 188.65% 145.32% 74.17% 203.63% 610.74% 242.76% 123.30%
Selling, General and Administrative Expense of Revenue
26,710.71% 0.00% 1,842.40% 960.53% 1,097.76% 670.79% 1,967.10% 965.36% 207.74% 89.86%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
2,496.43% 0.00% 265.59% 163.13% 163.56% 81.68% 220.93% 240.26% 53.71% 25.81%
Graham Net Nets
0.17 — 0.50 (0.07) (0.94) (0.71) (0.37) (0.06) (0.51) (0.14)
Graham Number
0.00 — 0.00 20.72 27.96 53.15 56.16 0.00 88.20 31.57
Earnings Yield
(32.46%) — (200.00%) 290.99% (51.79%) (38.71%) (31.75%) (35.50%) (54.15%) (36.86%)
Free Cash Flow Yield
(18.08%) — (140.87%) (185.32%) (47.42%) (38.18%) (32.71%) (22.16%) (33.47%) (28.66%)
Revenue per Share
0.00 0.00 0.05 0.24 0.47 1.27 0.58 0.74 3.41 7.66
Operating CF per Share
(0.27) (0.49) (1.23) (3.84) (5.01) (9.03) (12.93) (9.96) (12.70) (12.97)
Capex per Share
0.00 0.00 0.18 (0.28) (0.30) (0.44) (0.88) (0.28) (1.03) (1.64)
Free Cash Flow per Share
(0.27) (0.49) (1.04) (4.11) (5.31) (9.47) (13.80) (10.24) (13.72) (14.62)
Cash per Share
0.48 0.34 0.66 2.81 7.78 10.06 16.70 36.20 25.80 35.45
Shareholders Equity per Share
0.40 0.31 0.99 2.95 (5.99) (13.08) (10.46) 1.46 (15.57) (2.36)
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
0.40 0.31 0.99 2.95 (5.99) (13.08) (10.46) 1.46 (15.57) (2.36)
Free Cash Flow
(11.36) (12.68) (14.87) (30.38) (31.83) (40.36) (54.65) (29.89) (32.17) (33.11)
Working Capital
17.09 6.77 7.06 10.80 31.98 29.20 58.08 92.07 49.75 78.86
Capital Expenditures
— — 2.62 (2.05) (1.83) (1.85) (3.47) (0.82) (2.40) (3.72)
Net Current Asset Value
8.22 (0.82) 5.29 (1.11) (63.30) (75.21) (61.09) (8.29) (48.65) (16.28)
EV/EBIT
0.00 — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.00 — (4.03) 1.16 0.65 0.34 1.52 0.38 0.30 0.21
Price to Operating Income
0.00 — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.00 0.00 0.00 0.00 0.12 0.12 0.11 0.05 0.16 0.19
Cash ROIC
(30.37%) (75.21%) (63.31%) (63.37%) (129.70%) (447.90%) (109.59%) (24.51%) (74.72%) (34.31%)
Accounts Receivable Turnover
0.00 — 0.00 7.55 7.09 10.15 5.50 2.22 2.17 3.81
Accounts Payable Turnover
0.00 0.00 0.00 0.00 1.55 2.71 3.59 2.28 7.15 7.90
Inventory Turnover
— — — 0.00 2.74 2.45 3.28 4.39 6.85 9.40
Average Days of Payables
0.00 0.00 0.00 0.00 206.28 165.62 92.24 190.03 48.76 46.18
Days of Inventory on Hand
— — — 165.95 108.05 98.39 176.71 78.40 32.74 63.84
Average Receivables
— — — 0.23 0.40 0.53 0.42 0.97 3.68 4.56
Average Payables
0.61 1.00 1.30 1.69 2.43 2.23 1.90 1.75 1.49 1.56
Average Inventory
— — — 1.14 1.37 2.46 2.07 0.91 1.56 1.31
Average Assets
23.98 19.32 33.94 62.69 72.09 78.83 105.94 98.04 87.77 113.89
Average Common Equity
12.52 11.05 17.96 (7.04) (45.82) (48.58) (18.58) (16.13) (20.92) 13.89

Fold the line items

Columns are period end dates